Cocrystal Pharma (NASDAQ:COCP – Get Rating) had its price objective boosted by stock analysts at HC Wainwright to $42.00 in a report issued on Monday, MarketBeat Ratings reports. The brokerage currently has a “buy” rating on the stock.
Cocrystal Pharma Price Performance
COCP stock opened at $2.99 on Monday. The company has a market cap of $24.28 million, a P/E ratio of -0.69 and a beta of 0.93. Cocrystal Pharma has a 1 year low of $2.05 and a 1 year high of $11.88. The stock’s fifty day moving average price is $3.29 and its 200-day moving average price is $4.42.
Cocrystal Pharma (NASDAQ:COCP – Get Rating) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.48) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.48). As a group, analysts expect that Cocrystal Pharma will post -1.86 earnings per share for the current year.
About Cocrystal Pharma
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.
- Get a free copy of the StockNews.com research report on Cocrystal Pharma (COCP)
- The Cheesecake Factory Shows You Can Have It and Eat It Too
- Two EV Stocks That Could Rally Into Year-End
- 3 High Yields The Institutions Are Buying
- Can Activision Blizzard Rally Into Year End?
- Despite Financials, Twiliio is One To Watch
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.